Akèy › Kansè poumon › Iowa › Cedar Rapids
Etid klinik pou Kansè poumon nan Cedar Rapids, IA
14 etid pou Kansè poumon ap chèche patisipan nan sit nan ak bò kote Cedar Rapids (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ap rekriteFaz 3
- Physicians' Clinic of Iowa PC, Cedar Rapids
- Mercy Hospital, Cedar Rapids
- Oncology Associates at Mercy Medical Center, Cedar Rapids
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Mercy Hospital, Cedar Rapids
- Oncology Associates at Mercy Medical Center, Cedar Rapids
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Ap rekriteFaz 3
- Mercy Hospital, Cedar Rapids
- Oncology Associates at Mercy Medical Center, Cedar Rapids
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Ap rekriteFaz 3
- University of Iowa Hospitals & Clinics, Iowa City · 25 mi lwen
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Local Institution - 0065, Iowa City · 25 mi lwen
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Ap rekriteFaz 2/3
- Physicians Clinic of Iowa, Cedar Rapids
- Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City · 25 mi lwen
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- University of Iowa, Iowa City · 25 mi lwen
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
Ap rekriteFaz 3
- Helen G. Nassif Community Cancer Center, Cedar Rapids
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Saint Luke's Hospital, Cedar Rapids
CHAMP Lung Cancer Screening Program
Ap rekrite
- University of Iowa, Iowa City · 25 mi lwen
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Ap rekriteFaz 1/2
- University of Iowa Health Care, Iowa City · 25 mi lwen
Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
Ap rekriteFaz 2
- University of Iowa Hospitals and Clinics, Iowa City · 25 mi lwen
Using Xe MRI to Guide Radiation Therapy for Lung Cancer
Ap rekriteFaz 2
- University of Iowa, Iowa City · 25 mi lwen
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Iowa City · 25 mi lwen
Etid Kansè poumon nan lòt vil
- Houston, TX78 etid
- Boston, MA62 etid
- New York City, NY60 etid
- Los Angeles, CA45 etid
- Washington, DC41 etid
- Arlington, VA41 etid
- Chicago, IL41 etid
- Nashville, TN40 etid
- Baltimore, MD40 etid
- St. Louis, MO39 etid
- Columbus, OH37 etid
- Philadelphia, PA36 etid
Lòt etid nan Cedar Rapids
- Kansè Poumon ki pa ti selil20 etid
- Kansè nan tete17 etid
- Leksemi mieloïd egi16 etid
- Kansè (tout kalite)15 etid
- Myelom Miltip15 etid
- Kansè kolorektal13 etid
- Kansè pwostat12 etid
- Karsinòm selil skuamèz tèt ak kou12 etid
- Melanom10 etid
- Akidan serebavaskilè10 etid
- Kansè Metastatik9 etid
- Kansè Endomèt9 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.